Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01681446 |
Recruitment Status : Unknown
Verified May 2018 by Jia Fan, Fudan University.
Recruitment status was: Recruiting
First Posted : September 10, 2012
Last Update Posted : June 1, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatocellular Carcinoma | Drug: interferon-alpha (IFN-alpha) | Phase 3 |
BACKGROUND: Postoperative interferon-alpha (IFN-alpha) therapy improved survival in patients with hepatocellular carcinoma (HCC). MiR-26 is a predictive marker for the effect of postoperative interferon-alpha treatment in patients with HCC. Our study is to identify the effect of postoperative IFN-alpha treatment in patients with a low miR-26 expression in tumor after resection of HCC.
METHODS: A quantitative RT-PCR assays of miR-26 are performed on specimens which are collected from patients who underwent a curative resection of HCC. These patients with low miR-26 expression will return to the hospital 4 to 6 weeks after the resection following the baseline examination to rule out residual tumor. If all requirements are satisfied, these patients will be randomly assigned to the treatment group who received postoperative IFN-alpha therapy or the control group who will not receive any anti-cancer treatment. Disease-free survival, overall survival, time to recurrence and the side effects will be observed.
Anticipated RESULTS: IFN-alpha treatment improved the disease-free survival in patients with a low miR-26 expression in tumor after curative resection of HCC, probably by inhibiting tumor recurrence.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 296 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Effect of Postoperative Interferon-alpha Treatment in Patients Underwent Curative Surgery for Hepatocellular Carcinoma With a Low miR-26 Expression: a Multi-center Randomized Clinical Trial. |
Study Start Date : | August 2012 |
Estimated Primary Completion Date : | August 2019 |
Estimated Study Completion Date : | August 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: interferon-alpha (IFN-alpha)
interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
|
Drug: interferon-alpha (IFN-alpha)
interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
Other Names:
|
No Intervention: control
no anti-cancer interventions were assigned
|
- disease free survival [ Time Frame: 5 years ]interval between the dates of surgery and tumor recurrence or patient death
- overall survival [ Time Frame: 5 years ]interval between the dates of surgery and patient death
- time to recurrence [ Time Frame: 5 years ]interval between the dates of surgery and tumor recurrence
- Number of Participants with Adverse Events [ Time Frame: eighteen months ]Number of Participants with Adverse Events(hypohepatia,fever,leukopenia and thrombopenia)will be measured
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Perioperative Period Inclusion Criteria:
- Signed informed consent;
- Aged ≥ 18 years and ≤ 75 years old, male or female;
- Patients with a low miR-26 expression in tumor (confirmed by RT-PCR) underwent a curative resection of HCC;
-
The tumor characteristics must meet the following:
- tumor diameter is between 3 to 8 centimeters,and the number of tumor is less than 3
- no thrombosis is detected in the main branches of the portal vein, hepatic vein and bile duct by preoperative imaging or by intra-operative findings
- no extrahepatic and lymph node metastasis
Perioperative Period Exclusion Criteria:
- Concomitant malignant primary tumor(s) in other systems is/are present;
- The subject receives any previous systemic anti-HCC therapy prior to the resection surgery, such as liver transplantation, intervention, ablation, radiotherapy, chemotherapy, molecular targeted therapy or other anti-HCC therapy;
- The subject takes other study/investigational drugs during this study;
- The subject has cerebrovascular accident, renal insufficiency, depression, hyperthyreosis, hypothyroidism or other severe uncontrolled diseases;
- The subject has a history of study drug or similar drug allergy.
Baseline (Post-Surgery 4 to 6 weeks) Inclusion Criteria:
- Baseline (post-resection) blood routine examination shows that the number of leukocyte>2.5*10^9/L and platelet count>40*10^9/L;
- Child-Pugh score of class A at baseline.
Baseline (Post-Surgery 4 to 6 weeks) Exclusion Criteria:
- Concomitant malignant primary tumor(s) in other systems is/are present;
- The subject takes other study/investigational drugs within 4 weeks prior to randomization;
- The baseline examination indicates that infection, bleeding, bile leakage, or other postoperative complications are present;
- The baseline examination suggests the presence of tumor metastasis;
- The subject has cerebrovascular accident, renal insufficiency, depression, hyperthyreosis, hypothyroidism or other severe uncontrolled diseases;
- The subject has a history of investigational drug or similar drug allergy;
- The subject is pregnant, lactating, or urine pregnancy test result is positive.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01681446
Contact: Mei-ling Li | 64041990 ext 2936 | livercongress@zs-hospital.sh.cn |
China, Fujian | |
The Mengchao hepatobiliary hospital,Fujian Medical University,and Liver disease research center of Fujian province | Recruiting |
Fuzhou, Fujian, China | |
Contact: Jingfeng Liu drjingfeng@yahoo.com.cn | |
Principal Investigator: Jingfeng Liu | |
Zhongshan Hospital, Xiamen University | Recruiting |
Xiamen, Fujian, China, 361004 | |
Contact: Ping-Guo Liu, MD | |
Principal Investigator: Ping-Guo Liu, MD | |
China, Shanghai | |
Liver Cancer Institute and Zhongshan Hospital, Fudan University | Recruiting |
Shanghai, Shanghai, China, 200032 | |
Contact: Mei-ling Li 64041990 ext 2936 livercongress@zs-hospital.sh.cn | |
Principal Investigator: Jia Fan, MD | |
Sub-Investigator: Hui-Chuan Sun, MD | |
ShanghaiBio Coorperation | Recruiting |
Shanghai, Shanghai, China | |
Contact: Jason Gang Jin, PhD 13818588366 jasongjin@gmail.com | |
Principal Investigator: Jason Gang Jin, MD, PhD | |
China, Tianjin | |
Tumor Hospital, Tianjin Medical University | Recruiting |
Tianjin, Tianjin, China | |
Contact: Ti Zhang, MD zhangti2001@yahoo.com.cn | |
Principal Investigator: Qiang Li, MD | |
Sub-Investigator: Ti Zhang, MD |
Principal Investigator: | Jia Fan, MD, PHD | Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China | |
Principal Investigator: | Xin Wei Wang, PhD | National Cancer Institute, NIH, US |
Responsible Party: | Jia Fan, Professor of Surgery, Fudan University |
ClinicalTrials.gov Identifier: | NCT01681446 |
Other Study ID Numbers: |
LCI IFNa miR-26 |
First Posted: | September 10, 2012 Key Record Dates |
Last Update Posted: | June 1, 2018 |
Last Verified: | May 2018 |
hepatocellular carcinoma interferon-alpha miR-26 |
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site |
Digestive System Diseases Liver Diseases Interferons Interferon-alpha Antineoplastic Agents Antiviral Agents Anti-Infective Agents Immunologic Factors Physiological Effects of Drugs |